| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfb13bb80163a175d8a050092b335422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50872d0d223af7a5b710fba10c718b5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2457fa34d435d88f1d42732e4a779ec0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f5c1dcfc4ef150f1703898c3aa35c7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea40540de3bb66a98f4cbbd3d177d63c |
| publicationDate |
2015-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20150024342-A |
| titleOfInvention |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| abstract |
The present invention relates to a method of determining the level of expression of E-selectin, ICAM-1 or VEGFR-3, particularly plasma expression levels, compared to the control level of HER2 positive breast cancer, particularly those diagnosed as locally recurrent or metastatic HER2- (Avastin (R)) in the treatment of HER2-positive breast cancer, particularly in patients with locally recurrent or metastatic HER2-positive breast cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11674182-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190058082-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018164518-A1 |
| priorityDate |
2012-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |